4.5 Article

The first synthesis of [C-11]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3)

Journal

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 21, Issue 1, Pages 245-249

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2010.11.026

Keywords

[C-11]SB-216763; Glycogen synthase kinase-3 (GSK-3); Radiosynthesis; Positron emission tomography (PET); Cancer; Alzheimer's disease

Funding

  1. Breast Cancer Research Foundation of Indiana University
  2. Indiana Genomics Initiative (INGEN) of Indiana University
  3. Lilly Endowment Inc.
  4. NSF-MRI [CHE-0619254]

Ask authors/readers for more resources

SB-216763 is a novel, potent and selective glycogen synthase kinase-3 (GSK-3) inhibitor with an IC50 value of 34 nM. [C-11]SB-216763 (3-(2,4-dichlorophenyl)-4-(1-[C-11]methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione), a new potential PET agent for imaging of GSK-3, was first designed and synthesized in 20-30% decay corrected radiochemical yield and 370-555 GBq/mu mol specific activity at end of bombardment (EOB). The synthetic strategy was to prepare a carbon-11-labeled maleic anhydride intermediate followed by the conversion to maleimide. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available